NASDAQ$SPRY
ARS Pharmaceuticals Inc · Q1 2024 earnings
Q1 2024 earnings · · Investor relations
Briefing
ARS Pharmaceuticals reported first quarter 2024 financial results and highlighted regulatory progress for neffy.
ARS Pharmaceuticals reported a net loss of $10.3 million for Q1 2024, compared to a net loss of $15.0 million for Q1 2023. The company's cash and securities totaled $223.6 million as of March 31, 2024, which is expected to fund operations for at least three years. The company anticipates potential U.S. launch of neffy in the second half of 2024.
- Submitted response to FDA's Complete Response Letter (CRL) for neffy, with anticipated review completion by early October 2024.
- Submitted Day 180 response to EMA's CHMP for Marketing Authorization Application (MAA) for neffy, with CHMP opinion expected in the second quarter of 2024.
- Preparing to initiate outpatient study of neffy for urticaria (hives) in the second half of 2024.
- Cash and securities totaled $223.6 million as of March 31, 2024, providing an expected operating runway of at least three years.
Headline financials
Revenue & EPS history
ARS Pharmaceuticals · Revenue · Quarterly
$0
Revenue by segment
ARS Pharmaceuticals · $22.7M total across 3 segments · Q1 2026
- Product revenue, net$17.5M—76.9%
- Revenue under supply agreements$2.74M—12.1%
- Revenue under collaboration agreements$2.49M—11.0%
Forward guidance
ARS Pharma anticipates an FDA review period of up to six months, and the PDUFA date is anticipated to be October 2, 2024, based on the submission receipt date of April 2, 2024. Assuming approval on or before the anticipated PDUFA date, ARS Pharma anticipates launching neffy in the U.S. in the second half of 2024.
Tailwinds
- Potential approval of neffy for Type I allergic reactions.
- Potential U.S. launch of neffy in the second half of 2024.
- Planned submissions of neffy to other foreign regulatory authorities for approval.
- ARS Pharma believes to be well capitalized to support the launch of neffy in the U.S.
- Initiation of outpatient study of neffy for urticaria.
Headwinds
- Ability to obtain and maintain regulatory approval for neffy in any indication.
- New issues could be identified which could delay or prevent the approval of neffy.
- PDUFA target action date may be further delayed due to various factors outside ARS Pharma’s control.
- Potential safety and other complications from neffy.
- Uncertainties related to capital requirements.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q1 2024
-1.2%
Avg return
Earnings day
+0.7%
Avg return
5 days after
+2.4%
Avg return
30 days after
41%
9 / 22 earnings
Positive
+22.8%
Q4 2024
Best reaction
-15.1%
Q3 2024
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -6.2% | -1.5% | +23.1% | |
| Q4 2025 | -0.1% | -7.4% | -9.6% | |
| Q3 2025 | +0.8% | -7.2% | +18.0% | |
| Q2 2025 | -5.2% | -15.8% | -39.8% | |
| Q1 2025 | -9.4% | +6.8% | +15.3% | |
| Q4 2024 | +22.8% | +12.9% | +27.7% | |
| Q3 2024 | -15.1% | -17.0% | -28.4% | |
| Q2 2024 | +2.7% | +16.7% | +26.1% | |
| Q1 2024 | -3.5% | -0.9% | -2.8% | |
| Q4 2023 | -0.6% | +14.9% | -2.6% | |
| Q3 2023 | +4.2% | +18.2% | +48.6% | |
| Q2 2023 | -0.9% | +2.2% | +7.0% | |
| Q1 2023 | +1.6% | +6.6% | -23.6% | |
| Q4 2022 | -5.0% | -17.0% | -18.1% | |
| Q3 2022 | -1.5% | -5.5% | +13.5% | |
| Q2 2022 | +1.0% | +7.2% | +3.2% | |
| Q4 2021 | -8.8% | +11.7% | +44.1% | |
| Q1 2022 | -8.8% | -4.5% | -11.6% | |
| Q3 2021 | +0.2% | +3.5% | -17.1% | |
| Q2 2021 | +2.6% | -1.0% | -4.0% | |
| Q1 2021 | +9.1% | +3.2% | -21.0% | |
| Q4 2020 | -5.9% | -9.6% | +4.5% | |
| Q2 2020 | — | — | — | |
| Q1 2020 | — | — | — | |
| Q4 2019 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro